Key Takeaways for 2026 DSO Valuations
- DSO dental practice valuation multiples in 2026 typically range from 5x–8x normalized EBITDA for single-location practices and 8x–11x for multi-location practices over $1M in EBITDA, with many specialty practices receiving higher ranges at similar sizes.
- EBITDA is the primary profit metric DSOs and private equity buyers use, calculated after adjusting owner pay to a market-rate associate wage and removing personal or one-time expenses so it reflects transferable profitability.
- Key value drivers that can increase multiples include hygiene revenue above 30% of collections, associate depth, favorable payer mix, documented standard operating procedures (SOPs), multi-location scale, and well-documented financials.
- Pre-sale actions such as hiring producing associates, strengthening hygiene programs, cleaning up financials, and implementing SOPs can help a practice move toward the top of its likely multiple band.
- McLerran & Associates has facilitated more than 1,000 successful practice transitions and can provide a confidential, CPA-led valuation to show what your practice could realistically achieve in the current market.
How 2026 DSO EBITDA Multiples Tier by Practice Type
EBITDA, or earnings before interest, taxes, depreciation, and amortization, is the profit metric DSOs and private equity buyers typically use to price practices above roughly $1M–$1.5M in annual revenue. Unlike a simple percentage of collections, EBITDA reflects profit after normalizing owner compensation to a market-rate associate wage, removing personal or one-time expenses, and stress-testing the revenue that is likely to remain after the owner exits. The multiple applied to that EBITDA figure is what determines enterprise value.
Based on McLerran & Associates’ experience evaluating more than 10,000 dental practices and closing roughly 2,000 transactions representing approximately $2 billion in volume, the market shows a clear relationship between EBITDA scale and buyer type. Larger practices tend to attract institutional buyers willing to pay higher multiples, while smaller practices more often sell to regional DSOs or independent buyers at lower valuations. The following table illustrates how these multiples typically tier by practice size, consistent with data from FOCUS Investment Banking’s 2026 dental valuation framework, CT Acquisitions’ 2026 DSO M&A Multiples Report, and Provident Healthcare Partners’ Q1 2026 Dental Services Sector Update.
| Practice EBITDA Tier | Buyer Profile | 2026 EBITDA Multiple Range |
|---|---|---|
| Under $1M EBITDA | Small DSO tuck-in or independent buyer | 5x–7x |
| $1M–$3M EBITDA | Regional DSO add-on | 7x–9x |
| $3M–$5M EBITDA | Emerging platform or strategic acquirer | 9x–11x |
| $5M+ EBITDA | Platform-level private equity buyer | 10x–12x+ |
These figures represent ranges rather than guarantees. A specific practice’s position within its band can depend on the value drivers discussed below. FOCUS Investment Banking’s 2026 analysis notes that the gap between the best and middle-tier offers on any given practice has never been wider, so the process used to go to market can matter as much as the practice itself.
Find out which tier your practice likely falls into and what a competitive process could realistically deliver by requesting a confidential valuation analysis from McLerran & Associates.
Owner-Controlled Factors That Influence 2026 Multiples
DSO buyers focus on transferable EBITDA, meaning profit that can reasonably continue after the selling doctor steps away. Six owner-controlled factors can be some of the main influences on whether a practice lands at the top or bottom of its multiple band, each touching a different type of post-transition risk.
- Hygiene revenue above 30% of collections. Hygiene revenue above 30% of collections is one of the two highest-leverage value drivers and signals a stable, recall-driven patient base that tends to persist through an ownership change.
- Associate depth and reduced owner production. Adding one producing associate can move a practice up approximately one full turn of EBITDA because more production becomes transferable after the owner exits. Practices where the owner performs 90% or more of production can experience valuation reductions of 10–20%.
- Payer mix. Payer mix drove 1.0 to 2.0 turns of intra-band variance in recent transactions, with fee-for-service dominant practices near the top of ranges and Medicaid-heavy practices near the bottom.
- Documented SOPs and management depth. Trained non-owner management and documented standard operating procedures can add 1x–3x to EBITDA multiples by showing that the business runs independently of the owner.
- Multi-location scale. Moving from one to three locations can roughly double the EBITDA multiple by improving scale and broadening buyer appeal.
- Clean financials and defensible add-backs. Aggressive or undocumented add-backs are a frequent source of valuation disputes in due diligence. Practices that prepare 12–24 months in advance with clearly documented adjustments can often achieve stronger and more durable outcomes.
- Geographic market. Practices in high-growth metros such as Dallas, Houston, Atlanta, Phoenix, and Austin can command a 0.5–1x EBITDA premium from DSO buyers because of favorable demographic trends.
Revenue vs. EBITDA Multiples for $1.5M–$3M Practices
Owners in the $1.5M–$3M revenue range often see two very different-looking values depending on who prepares the valuation and for what purpose. Understanding why those values diverge can help clarify which transition path fits your situation.
A private buyer, typically an individual dentist using SBA financing, usually evaluates a practice based on collections or Seller’s Discretionary Earnings (SDE). SDE represents the total economic benefit to a single owner-operator. Private buyers generally pay 65–85% of annual gross collections, which for a $2M revenue practice with a 20% EBITDA margin translates to roughly $1.3M–$1.7M.
A DSO buyer prices the same practice on normalized EBITDA, which reflects profit after replacing the owner’s clinical production at a market-rate associate wage. That approach can result in a 40–80% premium over the private-buyer outcome for qualifying practices.
Each method reflects different buyer economics rather than a right or wrong answer. The key is knowing which market your practice can reasonably access and having a side-by-side comparison before you choose a direction. Because McLerran & Associates works both transition paths in roughly equal measure, it prepares that comparison for every client in this segment.
Specialty Practice Multiples in 2026
Specialty practices can command meaningful premiums over general dentistry at similar EBITDA tiers. These premiums often come from higher per-procedure margins, referral-network dynamics, and dedicated specialty DSO buyer pools. Orthodontics and oral and maxillofacial surgery frequently receive higher multiples than equivalent-sized general practices.
Pediatric dentistry practices can also command premiums, driven by similar referral-network economics and strong patient lifetime value. Endodontics and periodontics follow the same general pattern, although the size of their premiums can vary by market and by whether a specialty consolidator is actively building density in that area. Even general dentistry, while no longer at the 2021–2022 peak of 13x–16x, remains attractive as of mid-2026, with multiples that sit near all-time highs by historical standards outside that unusual period.
Pre-Sale Steps to Strengthen Your Multiple
Several practical steps can help a practice move toward the top of its likely multiple band. McLerran & Associates uses a CPA-led process to help owners prioritize and implement these steps before going to market.
- Hire and retain at least one producing associate 12–24 months before going to market to reduce owner-production concentration below 60% of total collections.
- Build and document a hygiene recall program targeting reappointment rates above 75% and the 30% hygiene revenue threshold discussed earlier.
- Clean up financials by reconciling 2–3 years of tax returns and practice management software reports, and document every add-back with clear supporting evidence.
- Reduce Medicaid exposure where feasible, or clearly document the stability and margin profile of that revenue stream.
- Implement and document standard operating procedures for scheduling, billing, and clinical protocols so the business demonstrably runs without the owner in the chair.
- Secure a lease with at least 5 years of remaining term, including renewal options, before going to market.
- Request a comprehensive, CPA-led practice valuation, rather than a quick free estimate, so you know your true EBITDA baseline and can track improvement over time.
Before you invest significant time in preparation, consider a free strategy conversation with McLerran & Associates to prioritize which of these steps can have the greatest impact for your specific practice.
Real-World Examples of 2026 Multiples
Real transaction outcomes can help show how process and positioning influence where a practice lands within its multiple band. McLerran & Associates’ history of DSO and private-buyer sales illustrates how disciplined preparation and competition can affect final value.
When Dr. William Pena engaged McLerran to advise on the sale of his 7-location pediatric group, offers were already on the table. McLerran’s CPA-led EBITDA analysis and competitive process produced a valuation roughly 20% higher than those initial offers, largely by controlling the profitability story and creating buyer competition instead of negotiating with a single DSO.
For Dr. Rob Gatewood and his partner, McLerran generated 8 offers for a highly productive multi-doctor practice that had grown beyond what any individual dentist buyer could finance. The competitive environment allowed the owners to maximize value while still selecting a partner that fit their clinical and cultural goals, not just the highest bidder.
These examples reflect a broader pattern. Practices taken to market through a structured multiple-buyer process can receive final transaction values that average about 30% above what many owners achieve when selling on their own. McLerran’s structured auction process, typically 45–60 days and often generating around 10 offers, is designed to create that type of competitive dynamic.
How to Secure a Defensible 2026 Valuation
A quick “free” valuation usually serves as a lead-generation tool and often becomes the buyer’s anchor in negotiation. When that number is not built from the ground up with proper add-back documentation, it can be reduced during due diligence and the deal terms can shift late in the process.
McLerran & Associates builds each valuation from a CPA-led EBITDA analysis. The team remotely accesses the practice’s management software, cross-references it with tax returns and financial statements, and reviews every discretionary, personal, and non-recurring expense to estimate normalized profitability. That diligence-grade work occurs before the practice goes to market so the valuation can withstand buyer scrutiny and the agreed value is less likely to erode before closing.
From that foundation, McLerran focuses on creating competition among buyers. A vetted pool of qualified groups, with poorly run DSOs excluded, receives a professional marketing deck and access to a virtual data room. This auction-style process can help practices reach or exceed the top of their applicable multiple band and supports McLerran’s transaction rate, which remains well above typical industry norms.
Frequently Asked Questions
What multiple will my practice sell for in 2026?
No advisor can responsibly quote a specific multiple without first reviewing your actual financials. The range your practice falls into can depend on normalized EBITDA, how much production depends on the owner, hygiene revenue as a percentage of collections, payer mix, number of locations and providers, and the level of buyer competition in your market. A CPA-led valuation, rather than a quick free estimate, is the most reliable way to establish a defensible baseline. McLerran & Associates evaluates more than 500 practices per year and can explain where your numbers currently land and which levers are available to adjust them before you go to market.
Is now a good time to sell to a DSO?
Demand for well-run practices remains strong in 2026, and multiples, while below the 2021–2022 peak, remain near historically attractive levels for practices that qualify for institutional buyers. A more practical question is whether your practice is currently positioned to attract the right buyer pool and reach the top of its likely multiple band. Market timing can matter, but preparation timing often matters more. McLerran can provide a candid view of how your practice is positioned today and, if you are not ready, can update your valuation later rather than encourage a sale before you feel prepared.
How is a DSO valuation different from what a private buyer would pay?
Private buyers, usually individual dentists using bank or SBA financing, tend to price practices as a percentage of annual collections or a multiple of Seller’s Discretionary Earnings, which reflects the total economic benefit to a single owner-operator. DSOs and private equity buyers price on normalized EBITDA, calculated after replacing the owner’s clinical production at a market-rate associate wage. For practices in the $1.5M–$3M revenue range, the DSO approach can produce a valuation 40–80% higher than the private-buyer approach on the same practice. The better path can depend on your practice’s size, profitability, and your personal goals, which is why McLerran prepares a side-by-side comparison for owners in this segment.
What happens to the equity portion of a DSO deal?
Most DSO transactions close with 60–75% of the purchase price paid as cash at closing, with the remainder structured as rollover equity and, in some cases, an earnout. Rollover equity can be held at the joint-venture level, tied to your specific practice with distributions, or at the holding-company level, tied to the entire DSO platform with a higher potential upside but no current distributions. As much as 40% of a deal can be paid in equity, which effectively makes you an investor in the DSO. McLerran helps clients evaluate that investment by reviewing the DSO’s profitability, growth trajectory, management team, and private equity backing so the equity portion is sized and structured thoughtfully.
Conclusion: Positioning Your Practice in the 2026 Market
In 2026, DSO dental practice valuation multiples function as ranges shaped by EBITDA scale, associate depth, hygiene performance, payer mix, specialty focus, and the competitive dynamics created by the sale process. As outlined earlier, multiples tend to increase with EBITDA, from the lower ranges for smaller practices to 10x–12x or higher for platform-grade groups, with many specialty practices earning premiums at similar size tiers. The gap between top-tier and mid-tier offers has widened, so the way a practice goes to market can significantly influence the final outcome.
McLerran & Associates has guided owners through roughly 2,000 successful practice sales representing approximately $2 billion in closed transaction volume, supported by more than 10,000 CPA-led evaluations. The firm works both private-buyer and DSO paths, runs a structured competitive process that often generates around 10 offers, and maintains a transaction rate that significantly exceeds typical industry results. The goal is a practice sale that closes at a fair price, with a buyer that fits your clinical philosophy, on terms that help protect what you have built.
Schedule a free, confidential discovery call with McLerran & Associates to explore what your practice may be worth in the 2026 market and which transition path could fit your goals. Call (512) 900-7989, email info@dentaltransitions.com, or visit the contact page.
